November 14, 2026

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001

Scrip No. 543916

Subject: Intimation pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") - Outcome of the Board Meeting - Financial Results

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of the SEBI Listing Regulations, please take note that the Board of Directors of the Company has, at its Meeting held today i.e., November 14, 2026, considered and approved, inter-alia, the Un-audited Financial Results (standalone and consolidated) of the Company for the half year ended September 30, 2026 along with the Limited Review Report of the Statutory Auditors thereon.

The said results along with the Limited Review Report is annexed herewith.

The above information is also available on the website of the Company i.e., www.hemantsurgical.com

The Board Meeting commenced at 02:30 p.m. and concluded at 03:10 p.m.

Kindly take same on records.

Thanking You,

Yours faithfully,
For Hemant Surgical Industries Limited

HANSKUMAR SHAMJI SHAH
Digitally signed by HANSKUMAR SHAMJI SHAH
Date: 2026.11.14 16:01:20 +05'30'

Hanskumar Shamji Shah
Managing Director
DIN: 00215972
Email id: hanskumar@hemantsurgical.com

A D V & ASSOCIATES
CHARTERED ACCOUNTANTS

807, Metroplex, 14 B Wing
Malad west, Offlink Road
Mindspace complex,
Mumbai – 400064
Tel : 9029059911
Email : advassociates@gmail.com

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of Hemant Surgical Industries Limited for the half year ended September 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Hemant Surgical Industries Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Hemant Surgical Industries Limited** ("the Company") for the half year ended September 30, 2026, together with the Statement of Assets and Liabilities as at that date and the Statement of Cash Flows for the half year then ended ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

A D V & ASSOCIATES
CHARTERED ACCOUNTANTS

807, Metroplex, 14 B Wing
Malad west, Offlink Road
Mindspace complex,
Mumbai – 400064
Tel : 9029059911
Email : advassociates@gmail.com

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in AS 25 prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A D V & Associates
Chartered Accountants
Firm Registration No.: 128045W

Pratik Kabra
Digitally signed by Pratik Kabra
Date: 2026.11.14 15:23:03 +05'30'

Pratik Kabra
Partner
Membership No.: 611401
UDIN: 26611401XZMURT8714
Place: Mumbai
Date: November 14, 2026

HEMANT SURGICAL INDUSTRIES LIMITED
CIN :L33110MH1989PLC051133
ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080
Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(₹ In lakhs except EPS)

Particulars	Half Year Ended			Year Ended
	September 30, 2026	March 31, 2026	September 30, 2025	March 31, 2026
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from Operations	27,592.01	16,672.65	6,426.06	23,098.71
II. Other Incomes	227.72	339.30	233.43	572.73
III. Total Revenue (a)	**27,819.73**	**17,011.95**	**6,659.49**	**23,671.44**
IV. Expenses				
1. Cost of Raw Materials Consumed	20,053.54	14,551.27	4,188.19	18,739.46
2. Change in Inventories	1,272.46	(1,404.65)	442.08	(962.56)
3. Employee Benefits Expenses	630.08	511.95	484.91	996.85
4. Finance Costs	115.99	201.18	195.33	396.51
5. Depreciation	117.76	78.89	73.29	152.18
6. Other Expenses	2,866.96	1,432.62	553.37	1,986.00
V. Total Expenses (b)	**25,056.80**	**15,371.26**	**5,937.17**	**21,308.43**
VI. Profit before Exceptional and Extraordinary Items and Tax	**2,762.93**	**1,640.69**	**722.32**	**2,363.01**
VII. Exceptional Items	-	-	-	-
VIII. Profit Before Extraordinary items and Tax	**2,762.93**	**1,640.69**	**722.32**	**2,363.01**
IX. Extraordinary Items	-	-	-	-
X. Profit before tax	**2,762.93**	**1,640.69**	**722.32**	**2,363.01**
XI. Tax Expense				
a. Current Tax	658.78	343.72	143.32	487.04
b. Earlier Year Tax	-	(61.71)	-	(61.71)
c. Deferred Tax Expenses (Income)	192.40	75.86	38.48	114.34
XII. Profit for the period from Continuing Operations	**1,911.75**	**1,282.81**	**540.53**	**1,823.34**
XIII. Profit from Discontinuing Operations		-	-	-
XIV. Tax Expense of Discontinuing Operations		-	-	-
XV. Profit from Discontinuing Operations after Tax		-	-	-
XVI. Profit for the period	**1,911.75**	**1,282.81**	**540.53**	**1,823.34**
Paid up Equity share Capital (Equity Shares of Face Value Rs 10 Each)	1,453.76	1,303.84	1,303.84	1,303.84
Reserve and Surplus Excluding Revaluation Reserve				11,412.67
XVII. Earning per Equity Share of face value of Rs 10 each (EPS of Half Year Ended has not been Annualised)				
(a) Basic EPS	13.49	10.85	5.09	15.42
(b) Diluted EPS	13.23	10.54	5.05	14.98

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: November 14, 2026

HEMANT SURGICAL INDUSTRIES LIMITED ★ MUMBAI

HEMANT SURGICAL INDUSTRIES LIMITED
CIN :L33110MH1989PLC051133
ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080
Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026

(₹ in Lakhs)

	Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
I	**Equity & Liabilities**		
	1.Shareholders funds:		
	a. Share Capital	1,453.76	1,303.84
	b. Reserves and Surplus	16,127.93	11,412.67
	c. Money Received against Share Warrants	295.50	1,033.86
	2.Non-Current liabilities:		
	a. Long-Term Borrowings	-	288.36
	b. Deferred Tax Liabilities(Net)	113.92	-
	c. Long Term Provisions	66.82	63.99
	3.Current Liabilities:		
	a. Short Term Borrowings	2,515.49	4,678.12
	b. Trade Payables		
	i. Micro enterprises and small enterprises	292.85	226.39
	ii. Other than micro enterprises and small enterprises.	6,300.07	6,894.13
	c. Other Current Liabilities	2,620.56	1,125.77
	d. Short Term Provisions	722.47	373.61
	Total	**30,509.37**	**27,400.73**
II	**Assets**		
	1.Non-Current Assets:		
	a. Property, Plant & Equipment and Intangible Assets	5,400.88	5,339.64
	b. Capital Work in progress	26.00	-
	c .Non-Current Investments	2,070.05	20.25
	d. Deferred Tax assets(net)	-	78.48
	e. Long Term Loans & Advances	1,165.31	2,259.02
	f. Other Non Current Assets	116.33	500.86
	2.Current Assets:		
	a. Current Investments		
	b. Inventories	4,506.80	5,865.29
	c. Trade Receivables	7,563.99	6,724.81
	d. Cash and Cash Equivalents	5,904.07	4,383.11
	e. Short Term Loans and Advances	1,953.76	908.79
	f. Other Current Assets	1,802.17	1,320.48
	Total	**30,509.37**	**27,400.73**

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

HEMANT SURGICAL INDUSTRIES LIMITED ★ MUMBAI

Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: November 14, 2026

HEMANT SURGICAL INDUSTRIES LIMITED

CIN :L33110MH1989PLC051133

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080

Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(₹ in Lakhs)

	Particulars	For the half year ended September 30, 2026 (Unaudited)	For the half year ended September 30, 2025 (Unaudited)
A	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Net Profit before tax as per Profit And Loss A/c	2,762.93	722.32
	Adjustments for:		
	Depreciation & Amortisation Expense	117.76	73.29
	Interest Income	(101.29)	(45.11)
	Profit on Sale of Fixed Assets	(53.18)	(109.11)
	Finance Cost	115.99	195.33
	Provision for Gratuity	14.48	4.78
	Operating Profit Before Working Capital Changes	**2,856.70**	**841.50**
	Changes in Working Capital		
	Adjusted for (Increase) Decrease in:		
	Trade Payables	(527.60)	(1,545.72)
	Other Current Liabilities	1,494.79	(53.60)
	Short term provision	(9.97)	-
	Inventories	1,358.49	536.80
	Trade Receivables	(839.18)	(672.53)
	Loans and Advances	(1,044.97)	(122.73)
	Other current assets	(481.69)	(50.87)
	Cash Generated From Operations	**2,806.57**	**(1,067.16)**
	Net Income Tax paid/ refunded	(311.60)	(90.94)
	Net Cash Flow from/(used in) Operating Activities: (A)	**2,494.97**	**(1,158.10)**
B	Cash Flow From Investing Activities:		
	Purchases of property, plant and equipment (including capital work in progress)	(322.18)	(582.34)
	Sales of property, plant and equipment	170.35	715.00
	Interest Income	101.29	45.11
	Changes in Fixed Deposit	979.19	(2,026.32)
	Acquisition of Subsidiary	(1,999.80)	-
	Net Increase (Decrease) in Non Current Investment	(50.00)	-
	Net Increase (Decrease) in Other Non Current Assets	1,478.24	114.65
	Net Cash Flow from/(used in) Investing Activities: (B)	**357.08**	**(1,733.90)**
C	Cash Flow from Financing Activities:		
	Net Increase (Decrease) in Long Term Borrowings	(288.36)	(598.70)
	Net Increase (Decrease) in Short Term Borrowings	(2,162.62)	2,815.97
	Proceeds from issue of equity shares and share warrants (net of issue expenses)	2,215.07	5,451.51
	Finance Cost	(115.99)	(195.33)
	Net Cash Flow from/(used in) Financing Activities (C)	**(351.90)**	**7,473.46**
D	Net Increase (Decrease) in Cash & Cash Equivalents (A+B+C)	2,500.15	4,581.46
	Cash & Cash Equivalents As At Beginning of the Period	1,759.53	373.84
	Cash & Cash Equivalents as at end of the Period	**4,259.68**	**4,955.30**

Component of cash and Bank Balances:

Particulars	For the half year ended September 30, 2026 (Unaudited)	For the half year ended September 30, 2025 (Unaudited)
i. Cash on hand	77.92	54.75
ii. Balance with Banks		
a. in current accounts	2,309.17	320.23
b. FD with maturity Less than 3 Months	1,872.59	4,580.33
Total	**4,259.68**	**4,955.30**

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: November 14, 2026

HEMANT SURGICAL INDUSTRIES LIMITED ★ MUMBAI

HEMANT SURGICAL INDUSTRIES LIMITED
CIN :L33110MH1989PLC051133
ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080
Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

NOTES TO STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

1. The above unaudited standalone financial results of the Company for the half year ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 14, 2026. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, these results have been subjected to limited review by the Statutory Auditors of the Company.

2. The above unaudited standalone financial results for the half year ended September 30, 2026 have been prepared in accordance with the recognition and measurement principles of Accounting Standard (AS) 25, Interim Financial Reporting, and the other Accounting Standards notified under Section 133 of the Companies Act, 2013, read with the Companies (Accounting Standards) Rules, 2021, and other accounting principles generally accepted in India. They have been prepared on the historical cost basis, on the accrual basis of accounting, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as

3. The Company's equity shares are listed on the SME platform of BSE Limited. Accordingly, in terms of Rule 4(2)(a) of the Companies (Indian Accounting Standards) Rules, 2015, the Company is not required to apply Indian Accounting Standards (Ind AS).

4. On June 1, 2026, the Company acquired 6,666 equity shares (66.66%) of Lifesenz Cancer Research Labs Private Limited ("Lifesenz") for ₹1,999.80 lakhs from related parties: 3,333 shares each from Mr. Hanskumar Shamji Shah, Managing Director, and Mr. Kaushik Hanskumar Shah, Whole-time Director & CFO. The price of ₹30,000 per share is based on the valuation report of a Registered Valuer dated May 26, 2026, pursuant to Share Purchase Agreements dated 27 May, 2026. Lifesenz is a subsidiary of the Company with effect from June 1, 2026, and is included in the consolidated results published separately.

5. The Company is operating in a Single Segment. Hence, the above financial results are based on single segment only.

6. Basic earnings per share is calculated by dividing the profit for the period by the weighted average number of equity shares outstanding during the period. For this, the equity shares allotted on conversion of share warrants are counted from their date of allotment. Diluted earnings per share also includes the equity shares that would be issued on conversion of the outstanding share warrants. Earnings per share for the half years is not annualised.

7. In FY 2025-26, the Company allotted on a preferential basis 25,98,400 equity shares at ₹197 per share (₹5,118.85 lakhs) and, on September 16, 2025, 20,99,200 warrants at ₹197 per warrant on receipt of 25% (₹1,033.86 lakhs), convertible within 18 months of allotment, i.e. on or before March 15, 2027. During the half year, 14,99,200 warrants were converted into equity shares on receipt of the balance 75% (₹2,215.07 lakhs). ₹886.50 lakhs is receivable on the remaining 6,00,000 warrants. The utilisation of the proceeds of ₹8,367.78 lakhs received up to September 30, 2026, under Regulation 32 of the SEBI (LODR) Regulations, 2015, is as under:

(₹ in Lakhs)

Object of the Issue	Amount Allocated for the Object	Amount Utilised	Balance Available in Bank	Amount yet to be receivable form Warrants Holder
Capital expenditure towards development/setting up of new facilities and expansion of existing manufacturing facilities including strategic acquisition/investment	5,000.00	2,732.38	1,380.92	886.50
Augment working capital needs of the Company and its Subsidiaries	1,500.00	1,500.00		
Repayment of debt	1,700.00	1,700.00		
For general corporate purposes	1,054.27	1,054.27		
Total	9,254.27	6,986.85		

Out of the total proceeds of ₹8,367.77 Lakhs, the Company has utilised ₹6,986.85 Lakhs for the intended purposes. The balance amount of ₹ 1,380.92 Lakhs is currently lying in the Company's bank account. In Addition to above the company would going to receive ₹886.50 Lakhs at the time of conversion of the warrants.

8. The figures for the half year ended March 31, 2026 are the balancing figures between the audited figures for the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the first half of that financial year, i.e. the half year ended September 30, 2025, which were subjected to limited review by the Statutory Auditors.

9. The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

HEMANT SURGICAL INDUSTRIES LIMITED MUMBAI

Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place: Mumbai
Date: November 14, 2026

A D V & ASSOCIATES
CHARTERED ACCOUNTANTS

807, Metroplex, 14 B Wing
Malad west, Offlink Road
Mindspace complex,
Mumbai – 400064
Tel : 9029059911
Email : advassociates@gmail.com

Independent Auditor's Review Report on the Unaudited Consolidated Financial Results of Hemant Surgical Industries Limited for the half year ended September 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Hemant Surgical Industries Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Hemant Surgical Industries Limited** ("the Parent") and its two subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the half year ended September 30, 2026, together with the Consolidated Statement of Assets and Liabilities as at that date and the Consolidated Statement of Cash Flows for the half year then ended ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Parent's personnel and the personnel of its subsidiaries responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

   Parent: Hemant Surgical Industries Limited

   Subsidiaries:

   (i) Solar Opto-Medic Private Limited (wholly owned subsidiary)

   (ii) Lifesenz Cancer Research Labs Private Limited (subsidiary with effect from June 1, 2026)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in AS 25 prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A D V & Associates
Chartered Accountants
Firm Registration No.: 128045W

Pratik Kabra
Digitally signed by Pratik Kabra
Date: 2026.11.14 15:21:38 +05'30'

Pratik Kabra
Partner
Membership No.: 611401
UDIN: 26611401XNLEEL5284
Place: Mumbai
Date: November 14, 2026

HEMANT SURGICAL INDUSTRIES LIMITED
CIN :L33110MH1989PLC051133
ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080
Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026

(₹ in Lakhs)

	Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
I	**Equity & Liabilities**		
	1. Shareholders funds:		
	a. Share Capital	1,453.76	1,303.84
	b. Reserves and Surplus	16,086.65	11,426.71
	c. Money Received against Share Warrants	295.50	1,033.86
	2. Minority Interest	-	-
	3. Non-Current liabilities:		
	a. Long-Term Borrowings	-	288.36
	b. Deferred Tax Liabilities (net)	113.92	-
	c. Long Term Provisions	66.82	63.99
	4. Current Liabilities:		
	a. Short Term Borrowings	2,519.87	4,678.12
	b. Trade Payables		
	i. Micro enterprises and small enterprises	292.85	226.39
	ii. Other than micro enterprises and small enterprises.	6,304.14	6,904.72
	c. Other Current Liabilities	2,632.95	1,126.52
	d. Short Term Provisions	722.47	373.61
	Total	**30,488.92**	**27,426.11**
II	**Assets**		
	1. Non-Current Assets:		
	a. Property, Plant & Equipment and Intangible Assets	5,578.06	5,344.50
	b. Capital Work in progress	26.00	-
	c. Goodwill	2,254.95	-
	d. Non-Current Investments	50.00	-
	e. Deferred Tax assets(net)	0.19	78.59
	f. Long Term Loans & Advances	1,165.31	2,260.53
	g. Other Non Current Assets	118.42	500.86
	2. Current Assets:		
	a. Current Investments	-	-
	b. Inventories	4,543.99	5,904.98
	c. Trade Receivables	7,581.58	6,735.03
	d. Cash and Cash Equivalents	5,913.52	4,383.65
	e. Short Term Loans and Advances	1,421.79	896.98
	f. Other Current Assets	1,835.12	1,320.98
	Total	**30,488.92**	**27,426.11**

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

HEMANT SURGICAL INDUSTRIES LIMITED ★ MUMBAI

Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: November 14, 2026

HEMANT SURGICAL INDUSTRIES LIMITED
CIN :L33110MH1989PLC051133
ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080
Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(₹ in Lakhs)

Particulars	Half Year Ended			Year Ended
	September 30, 2026	March 31, 2026	September 30, 2025	March 31, 2026
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from Operations	27,631.06	16,718.65	6,462.01	23,180.66
II. Other Incomes	226.61	352.96	233.43	586.39
III. Total Revenue (a)	**27,857.67**	**17,071.61**	**6,695.43**	**23,767.05**
IV. Expenses				
1. Cost of Raw Materials Consumed	20,060.19	14,592.80	4,198.60	18,791.41
2. Change in Inventories	1,274.96	(1,380.65)	444.51	(936.14)
3. Employee Benefits Expenses	667.48	511.97	497.12	1,009.09
4. Finance Costs	116.02	201.24	195.33	396.57
5. Depreciation	127.38	79.58	73.97	153.55
6. Other Expenses	2,876.71	1,437.62	556.29	1,993.91
V. Total Expenses (b)	**25,122.74**	**15,442.57**	**5,965.83**	**21,408.40**
VI. Profit before Exceptional and Extraordinary Items and Tax	**2,734.93**	**1,629.04**	**729.61**	**2,358.65**
VII. Exceptional Items	-	-	-	-
VIII. Profit Before Extraordinary items and Tax	**2,734.93**	**1,629.04**	**729.61**	**2,358.65**
IX. Extraordinary Items	-	-	-	-
X. Profit before tax	**2,734.93**	**1,629.04**	**729.61**	**2,358.65**
XI. Tax Expense				
a. Current Tax	658.78	341.83	145.21	487.04
b. Earlier Year Tax	-	(61.71)	-	(61.71)
c. Deferred Tax Expenses (Income)	192.33	75.80	38.42	114.22
XII. Profit for the period from Continuing Operations	**1,883.82**	**1,273.12**	**545.98**	**1,819.10**
XIII. Profit from Discontinuing Operations	-	-	-	-
XIV. Tax Expense of Discontinuing Operations	-	-	-	-
XV. Profit from Discontinuing Operations after Tax	-	-	-	-
XVI. Profit for the period	**1,883.82**	**1,273.12**	**545.98**	**1,819.10**
Net Profit attributable to:				
a) Owners of the Company	1,883.82	1,273.12	545.98	1,819.10
b) Minority Interest (Refer Note No: 8)	-	-	-	-
Paid up Equity share Capital (Equity Shares of Face Value Rs 10 Each)	1,453.76	1,303.84	1,303.84	1,303.84
Reserve and Surplus Excluding Revaluation Reserve				11,426.71
XVII. Earning per Equity Share of face value of Rs 10 each (EPS of Half Year Ended has not been Annualised)				
(a) Basic EPS	13.30	10.24	5.15	15.39
(b) Diluted EPS	13.03	9.84	5.10	14.94

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: November 14, 2026

HEMANT SURGICAL INDUSTRIES LIMITED ★ MUMBAI

HEMANT SURGICAL INDUSTRIES LIMITED
CIN : L33110MH1989PLC051133
ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080
Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747
CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(₹ in lakhs)

	Particulars	For the Half Year Ended September 30, 2026 (Unaudited)	For the Half Year Ended September 30, 2025 (Unaudited)
A	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Net Profit before tax as per Profit And Loss A/c	2,734.93	729.61
	Adjustments for:		
	Depreciation & Amortisation Expense	127.38	73.97
	Interest Income	(101.29)	(45.11)
	Profit on Sale of Fixed Assets	(53.18)	(109.11)
	Finance Cost	116.02	195.33
	Provision for Gratuity	14.48	4.78
	Operating Profit Before Working Capital Changes	**2,838.35**	**849.47**
	Changes in Working Capital		
	Adjusted for (Increase)/ Decrease in:		
	Trade Payables	(536.03)	(1,555.05)
	Other Current Liabilities	1,498.23	(62.09)
	Short term provision	(9.97)	21.74
	Inventories	1,360.99	539.23
	Trade Receivables	(846.62)	(684.08)
	Loans and Advances	(1,028.34)	21.21
	Other current assets	(478.37)	(50.78)
	Cash Generated From Operations	**2,798.24**	**(920.36)**
	Net Income Tax paid/ refunded	(311.60)	(90.94)
	Net Cash Flow from/(used in) Operating Activities: (A)	**2,486.64**	**(1,011.30)**
B	Cash Flow From Investing Activities:		
	Net Purchases of Purchase of property, plant and equipment (including capital WIP)	(322.46)	(582.34)
	Sale of property, plant and equipment (including capital WIP)	170.35	715.00
	Interest Income	101.29	45.11
	Changes in Fixed Deposit	979.19	(2,026.32)
	Acquisition of Subsidiary (Net of Cash and Cash Equivalents Acquired)	(1,982.25)	-
	Net Increase/(Decrease) in Non Current Investment	(50.00)	-
	Net Increase/(Decrease) in Other Non Current Assets	1,478.24	(32.94)
	Net Cash Flow from/(used in) Investing Activities: (B)	**374.35**	**(1,881.49)**
C	Cash Flow from Financing Activities:		
	Net Increase/(Decrease) in Long Term Borrowings	(288.36)	(576.31)
	Net Increase/(Decrease) in Short Term Borrowings	(2,162.62)	2,746.06
	Proceeds from issue of equity shares and share warrants (net of issue expenses)	2,215.07	5,451.51
	Finance Cost	(116.02)	(195.33)
	Net Cash Flow from/(used in) Financing Activities (C)	**(351.94)**	**7,425.94**
D	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	2,509.06	4,533.15
	Cash & Cash Equivalents As At Beginning of the Period	1,760.07	434.10
	Cash & Cash Equivalents As At End of the Period	**4,269.13**	**4,967.25**

Component of cash and Bank Balances:

Particulars	For the Half Year Ended September 30, 2026 (Unaudited)	For the Half Year Ended September 30, 2025 (Unaudited)
i.Cash on hand	78.06	55.57
ii. Balance with Banks		
a. in current accounts	2,318.48	331.36
b. FD with maturity Less than 3 Months	1,872.59	4,580.33
Total	**4,269.13**	**4,967.25**

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: November 14, 2026

HEMANT SURGICAL INDUSTRIES LIMITED ★ MUMBAI

HEMANT SURGICAL INDUSTRIES LIMITED
CIN :L33110MH1989PLC051133
ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080
Website: www.hemantsurgical.com , Email: cs@hemantsurgical.com , Tel No: 022-25915289/022-25912747

NOTES TO CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

1. The above unaudited consolidated financial results of Hemant Surgical Industries Limited ("the Parent") and its subsidiaries (together "the Group") for the half year ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 14, 2026. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, these results have been subjected to limited review by the Statutory Auditors of the Parent.

2. The above unaudited consolidated financial results for the half year ended September 30, 2026 have been prepared in accordance with the recognition and measurement principles of Accounting Standard (AS) 25, Interim Financial Reporting, and the other Accounting Standards notified under Section 133 of the Companies Act, 2013, read with the Companies (Accounting Standards) Rules, 2021, and other accounting principles generally accepted in India. They have been prepared on the historical cost basis, on the accrual basis of accounting, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3. The Parent's equity shares are listed on the SME platform of BSE Limited. Accordingly, in terms of Rule 4(2)(a) of the Companies (Indian Accounting Standards) Rules, 2015, the Company is not required to apply Indian Accounting Standards (Ind AS).

4. The consolidated financial results comprise the financial results of Hemant Surgical Industries Limited ("the Parent") and its subsidiaries, Solar Opto-Medic Private Limited (a wholly-owned subsidiary) and Lifesenz Cancer Research Labs Private Limited (together, "the Group"). Lifesenz Cancer Research Labs Private Limited became a subsidiary with effect from June 1, 2026, on the acquisition of a 66.66% equity stake from Mr. Hanskumar Shamji Shah, Managing Director, and Mr. Kaushik Hanskumar Shah, Whole-time Director & CFO of the Parent. Its results have accordingly been included in the consolidated financial results from June 1, 2026. The consolidated financial results have been prepared in accordance with Accounting Standard (AS) 21, Consolidated Financial Statements, after eliminating all material intra-group balances and transactions.

5. Basic earnings per share is calculated by dividing the profit for the period by the weighted average number of equity shares outstanding during the period. For this, the equity shares allotted on conversion of share warrants are counted from their date of allotment. Diluted earnings per share also includes the equity shares that would be issued on conversion of the outstanding share warrants. Earnings per share for the half years is not annualised.

6. The Company is operating in a Single Segment. Hence, the above financial results are based on single segment only.

7. In FY 2025-26, the Parent Company allotted on a preferential basis 25,98,400 equity shares at ₹197 per share (₹5,118.85 lakhs) and, on September 16, 2025, 20,99,200 warrants at ₹197 per warrant on receipt of 25% (₹1,033.86 lakhs), convertible within 18 months of allotment, i.e. on or before March 15, 2027. During the half year, 14,99,200 warrants were converted into equity shares on receipt of the balance 75% (₹2,215.07 lakhs). ₹886.50 lakhs is receivable on the remaining 6,00,000 warrants. The utilisation of the proceeds of ₹8,367.78 lakhs received up to September 30, 2026, under Regulation 32 of the SEBI (LODR) Regulations, 2015, is as under:

(₹ in Lakhs)

Object of the Issue	Amount Allocated for the Object	Amount Utilised	Balance Available in Bank	Amount yet to be receivable form Warrants Holder
Capital expenditure towards development/setting up of new facilities and expansion of existing manufacturing facilities including strategic acquisition investment	5,000.00	2,732.58	1,380.92	886.50
Augment working capital needs of the Company and its Subsidiaries	1,500.00	1,500.00		
Repayment of debt	1,700.00	1,700.00		
For general corporate purposes	1,054.27	1,054.27		
Total	9,254.27	6,986.85		

Out of the total proceeds of ₹8,367.77 Lakhs, the Company has utilised ₹6,986.85 Lakhs for the intended purposes. The balance amount of ₹ 1,380.92 Lakhs is currently lying in the Company's bank account. In Addition to above the company would going to receive ₹886.50 Lakhs at the time of conversion of the warrants.

8. The losses of Lifesenz Cancer Research Labs Private Limited applicable to the minority shareholders exceed the minority interest in its equity. In accordance with paragraph 26 of Accounting Standard (AS) 21, Consolidated Financial Statements, such excess losses of ₹99.75 lakhs (₹94.19 lakhs at the date of acquisition and ₹5.56 lakhs for the period from June 1, 2026 to September 30, 2026) have been absorbed by the Parent, as the minority shareholders have no binding obligation to make good such losses. Accordingly, minority interest has been presented as nil. Any future profits of the subsidiary will be allocated to the Parent until the minority's share of losses so absorbed has been recovered.

9. The figures for the half year ended March 31, 2026 are the balancing figures between the audited figures for the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the first half of that financial year, i.e. the half year ended September 30, 2025, which were subjected to limited review by the Statutory Auditors.

10. The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hanskumar Shamji Shah
Managing Director
DIN - 00215972
Place: Mumbai
Date: November 14, 2026

HEMANT SURGICAL INDUSTRIES LIMITED ★ MUMBAI